Literature DB >> 28317080

The Critical Role of Imaging in the Management of Multiple Myeloma.

Shahzad Raza1, Siyang Leng2, Suzanne Lentzsch2.   

Abstract

Multiple myeloma (MM) is characterized by abnormal proliferation of plasma cells in the bone marrow leading to symptoms of anemia, renal failure, hypercalcemia, and bone lesions. Bone imaging is critical for the diagnosis, staging, assessment for the presence and extent of bone lesions, and initial treatment of MM. Skeletal survey is the preferred initial imaging modality due to its availability and low cost. However, it has poor sensitivity and patients with occult myeloma may escape detection, delaying their diagnosis and treatment. New cross-sectional imaging modalities such as low-dose whole body CT, MRI, and PET-CT have high sensitivity and specificity for detecting lytic lesions and extramedullary relapse in MM. The combined use of cross-sectional imaging may provide complimentary information for staging, prognosis, and disease monitoring. In this review, we will discuss commonly used imaging modalities and their advantages and disadvantages in the management of MM.

Entities:  

Keywords:  Bone; Imaging; MRI; Multiple myeloma; Pet

Mesh:

Year:  2017        PMID: 28317080     DOI: 10.1007/s11899-017-0379-9

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  47 in total

1.  Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates.

Authors:  A Stäbler; A Baur; R Bartl; R Munker; R Lamerz; M F Reiser
Journal:  AJR Am J Roentgenol       Date:  1996-10       Impact factor: 3.959

Review 2.  Bone marrow imaging.

Authors:  J B Vogler; W A Murphy
Journal:  Radiology       Date:  1988-09       Impact factor: 11.105

3.  Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography.

Authors:  Marius Horger; Claus D Claussen; Ulrike Bross-Bach; Reinhard Vonthein; Tobias Trabold; Martin Heuschmid; Christina Pfannenberg
Journal:  Eur J Radiol       Date:  2005-05       Impact factor: 3.528

4.  Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.

Authors:  K Detweiler Short; S V Rajkumar; D Larson; F Buadi; S Hayman; A Dispenzieri; M Gertz; S Kumar; J Mikhael; V Roy; R A Kyle; M Q Lacy
Journal:  Leukemia       Date:  2011-02-25       Impact factor: 11.528

Review 5.  State-of-the-art of bone marrow imaging in multiple myeloma.

Authors:  Luis Martí-Bonmatí; Cristina Ramirez-Fuentes; Ángel Alberich-Bayarri; Cristina Ruiz-Llorca
Journal:  Curr Opin Oncol       Date:  2015-11       Impact factor: 3.645

6.  Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Authors:  Meletios Dimopoulos; Robert Kyle; Jean-Paul Fermand; S Vincent Rajkumar; Jesus San Miguel; Asher Chanan-Khan; Heinz Ludwig; Douglas Joshua; Jayesh Mehta; Morie Gertz; Hervé Avet-Loiseau; Meral Beksaç; Kenneth C Anderson; Philippe Moreau; Seema Singhal; Hartmut Goldschmidt; Mario Boccadoro; Shaji Kumar; Sergio Giralt; Nikhil C Munshi; Sundar Jagannath
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

7.  Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.

Authors:  Gareth J Morgan; Faith E Davies; Walter M Gregory; Alex J Szubert; Sue E Bell; Mark T Drayson; Roger G Owen; A John Ashcroft; Graham H Jackson; J Anthony Child
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

8.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Authors:  Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

9.  Whole-body MRI versus whole-body MDCT for staging of multiple myeloma.

Authors:  Andrea Baur-Melnyk; Sonja Buhmann; Christoph Becker; Stefan Oswald Schoenberg; Nicola Lang; Reiner Bartl; Maximilian Ferdinand Reiser
Journal:  AJR Am J Roentgenol       Date:  2008-04       Impact factor: 3.959

Review 10.  Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting.

Authors:  Esther G M de Waal; Andor W J M Glaudemans; Carolien P Schröder; Edo Vellenga; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-29       Impact factor: 9.236

View more
  2 in total

1.  Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma.

Authors:  Enrico Caserta; Junie Chea; Megan Minnix; Erasmus K Poku; Domenico Viola; Steven Vonderfecht; Paul Yazaki; Desiree Crow; Jihane Khalife; James F Sanchez; Joycelynne M Palmer; Susanta Hui; Nadia Carlesso; Jonathan Keats; Young Kim; Ralf Buettner; Guido Marcucci; Steven Rosen; John Shively; David Colcher; Amrita Krishnan; Flavia Pichiorri
Journal:  Blood       Date:  2018-01-04       Impact factor: 22.113

2.  Improvement in the Symptoms and VEGF Levels after Resection of an Extrame Dullary Spinal Tumor and Additional Chemotherapy in a Patient with Multiple Myeloma Complicated with POEMS Syndrome.

Authors:  Mariko Sano; Tatou Iseki; Makoto Sasaki; Yutaka Tsukune; Hajime Yasuda; Kazo Kanazawa; Atsushi Arakawa; Kazumasa Yokoyama; Norio Komatsu; Nobutaka Hattori; Kenya Nishioka
Journal:  Intern Med       Date:  2021-11-15       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.